Laparoscopic cytoreductive nephrectomy is associated with significantly improved survival compared with open cytoreductive nephrectomy or targeted therapy alone

Zhao,Kaidong; Kim,Eric H.; Vetter,Joel M.; Hsieh,James J.; Venkatesh,Ramakrishna; Bhayani,Sam B.; Figenshau,R. Sherburne

doi:10.3892/mco.2020.2141

Laparoscopic cytoreductive nephrectomy is associated with significantly improved survival compared with open cytoreductive nephrectomy or targeted therapy alone

Authors:
- Kaidong Zhao
- Eric H. Kim
- Joel M. Vetter
- James J. Hsieh
- Ramakrishna Venkatesh
- Sam B. Bhayani
- R. Sherburne Figenshau
View Affiliations

Affiliations: Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, P.R. China, Division of Urologic Surgery, Washington University School of Medicine, St. Louis, MO 63110, USA, Division of Oncology, Washington University School of Medicine, St. Louis, MO 63110, USA
Published online on: September 21, 2020 https://doi.org/10.3892/mco.2020.2141
Article Number: 71

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to compare the survival outcomes for patients with metastatic renal cell carcinoma (mRCC) who underwent laparoscopic cytoreductive nephrectomy (CN) vs. open CN vs. targeted therapy (TT) alone at our institution. A retrospective chart review was performed at our institution for patients who underwent CN prior to TT (laparoscopic, n=48; open, n=48) or who were deemed unfit for surgery and received TT alone (n=36), between January 2007 and December 2012. Kaplan‑Meier estimated survival and Cox proportional hazards analyses were performed. Laparoscopic CN was associated with significantly longer survival compared with open CN or TT alone (median survival 24 vs. <12 months, respectively; P<0.01). On multivariate analysis, laparoscopic CN was an independent predictor of survival [hazard ratio (HR)=0.48, P<0.01), controlling for preoperative risk factors, while survival was similar between open CN and TT alone (HR=0.85, P=0.54). In our experience, laparoscopic CN appears to be a significant predictor of survival in mRCC. Selection bias of the surgeon for patients with improved survival may account for clinical variables that were otherwise difficult to quantify. For patients who were not candidates for laparoscopic CN, open CN did not confer a survival benefit over TT alone, while it was associated with increased morbidity.

View Figures

View References

1	Walther MM, Yang JC, Pass HI, Linehan WM and Rosenberg SA: Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma. J Urol. 158:1675–1678. 1997.PubMed/NCBI View Article : Google Scholar
2	Mickisch GH, Garin A, van Poppel H, de Prijck L and Sylvester R: European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: A randomised trial. Lancet. 358:966–970. 2001.PubMed/NCBI View Article : Google Scholar
3	Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JR Jr, Munshi N and Crawford ED: Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 345:1655–1659. 2001.PubMed/NCBI View Article : Google Scholar
4	Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A and Ferrara J: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 17:2530–2540. 1999.PubMed/NCBI View Article : Google Scholar
5	Fallick ML, McDermott DF, LaRock D, Long JP and Atkins MB: Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma. J Urol. 158:1691–1695. 1997.PubMed/NCBI View Article : Google Scholar
6	Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, Heng DY, Larkin J and Ficarra V: Renal cell carcinoma. Nat Rev Dis Primers. 3(17009)2017.PubMed/NCBI View Article : Google Scholar
7	Choueiri TK and Motzer RJ: Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med. 376:354–366. 2017.PubMed/NCBI View Article : Google Scholar
8	Choueiri TK, Xie W, Kollmannsberger C, North S, Knox JJ, Lampard JG, McDermott DF, Rini BI and Heng DY: The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol. 185:60–66. 2011.PubMed/NCBI View Article : Google Scholar
9	Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, et al: Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: Results from a large, multicenter study. J Clin Oncol. 27:5794–5799. 2009.PubMed/NCBI View Article : Google Scholar
10	Culp SH, Tannir NM, Abel EJ, Margulis V, Tamboli P, Matin SF and Wood CG: Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy. Cancer. 116:3378–3388. 2010.PubMed/NCBI View Article : Google Scholar
11	Manley BJ, Kim EH, Vetter JM, Potretzke AM and Strope SA: Validation of preoperative variables and stratification of patients to help predict benefit of cytoreductive nephrectomy in the targeted therapy ERA. Int Braz J Urol. 43:432–439. 2017.PubMed/NCBI View Article : Google Scholar
12	Kerbl DC, McDougall EM, Clayman RV and Mucksavage P: A history and evolution of laparoscopic nephrectomy: Perspectives from the past and future directions in the surgical management of renal tumors. J Urol. 185:1150–1154. 2011.PubMed/NCBI View Article : Google Scholar
13	Walther MM, Lyne JC, Libutti SK and Linehan WM: Laparoscopic cytoreductive nephrectomy as preparation for administration of systemic interleukin-2 in the treatment of metastatic renal cell carcinoma: A pilot study. Urology. 53:496–501. 1999.PubMed/NCBI View Article : Google Scholar
14	Rabets JC, Kaouk J, Fergany A, Finelli A, Gill IS and Novick AC: Laparoscopic versus open cytoreductive nephrectomy for metastatic renal cell carcinoma. Urology. 64:930–934. 2004.PubMed/NCBI View Article : Google Scholar
15	Eisenberg MS, Meng MV, Master VA, Stoller ML, Rini BI, Carroll PR and Kane CJ: Laparoscopic versus open cytoreductive nephrectomy in advanced renal-cell carcinoma. J Endourol. 20:504–508. 2006.PubMed/NCBI View Article : Google Scholar
16	Piccirillo JF and Feinstein AR: Clinical symptoms and comorbidity: Significance for the prognostic classification of cancer. Cancer. 77:834–842. 1996.PubMed/NCBI
17	Zlatev DV, Ozambela M, Salari K, Wang Y, Mossanen M, Pucheril D, Ingham MD, Chung BI and Chang SL: Trends and morbidity for minimally invasive versus open cytoreductive nephrectomy in the management of metastatic renal cell carcinoma. J Clin Oncol. 36 (Suppl 6)(S632)2018.
18	Gershman B, Moreira DM, Boorjian SA, Lohse CM, Cheville JC, Costello BA, Leibovich BC and Thompson RH: Comprehensive characterization of the perioperative morbidity of cytoreductive nephrectomy. Eur Urol. 69:84–91. 2016.PubMed/NCBI View Article : Google Scholar
19	Nunez Bragayrac L, Hoffmeyer J, Abbotoy D, Attwood K, Kauffman E, Spiess P, Wagner A and Schwaab T: Minimally invasive cytoreductive nephrectomy: A multi-institutional experience. World J Urol. 34:1651–1656. 2016.PubMed/NCBI View Article : Google Scholar
20	Zini L, Capitanio U, Perrotte P, Jeldres C, Shariat SF, Arjane P, Widmer H, Montorsi F, Patard JJ and Karakiewicz PI: Population-based assessment of survival after cytoreductive nephrectomy versus no surgery in patients with metastatic renal cell carcinoma. Urology. 73:342–346. 2009.PubMed/NCBI View Article : Google Scholar
21	Hanna N, Sun M, Meyer CP, Nguyen PL, Pal SK, Chang SL, de Velasco G, Trinh QD and Choueiri TK: Survival analyses of patients with metastatic renal cancer treated with targeted therapy with or without cytoreductive nephrectomy: A national cancer data base study. J Clin Oncol. 34:3267–3275. 2016.PubMed/NCBI View Article : Google Scholar
22	Stewart GD, Aitchison M, Bex A, Larkin J, Lawless C, Méjean A, Nathan P, Oades G, Patard JJ, Paul J, et al: Cytoreductive nephrectomy in the tyrosine kinase inhibitor era: A question that may never be answered. Eur Urol. 71:845–847. 2017.PubMed/NCBI View Article : Google Scholar
23	Pindoria N, Raison N, Blecher G, Catterwell R and Dasgupta P: Cytoreductive nephrectomy in the era of targeted therapies: A review. BJU Int. 120:320–328. 2017.PubMed/NCBI View Article : Google Scholar
24	Shuch B, Hanley J, Lai J, Vourganti S, Kim SP, Setodji CM, Dick AW, Chow WH and Saigal C: Urologic Diseases in America Project. Overall survival advantage with partial nephrectomy: A bias of observational data? Cancer. 119:2981–2989. 2013.PubMed/NCBI View Article : Google Scholar